FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 12:24:37 25/05/2024 am IST | ||
| 8.32 EUR | -0.60% |
|
| Current month | -9.86% | ||
| 1 month | -13.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 8.32 | -0.60% |
| 23/24/23 | 8.37 | -2.67% |
| 22/24/22 | 8.6 | -2.27% |
| 21/24/21 | 8.8 | +0.69% |
| 20/24/20 | 8.74 | -2.78% |
Delayed Quote Börse Stuttgart
Last update May 25, 2024 at 12:24 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF2 |
| ISIN | DE000MG1SF25 |
| Date issued | 05/04/2024 |
| Strike | 1,406 kr |
| Maturity | Unlimited |
| Parity | 7.55 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.59 € |
|---|---|
| Lowest since issue | 8.27 € |
| Spread | 0.02 € |
| Spread % | 0.24% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- Certificat
